Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett’s oesophagus for 1 year-Reference-Cited by-同舟云学术

Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett’s oesophagus for 1 year

Published:2011-03-08 Issue:9 Volume:33 Page:1019-1027
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

de Bortoli N.,Martinucci I.,Piaggi P.,Maltinti S.,Bianchi G.,Ciancia E.,Gambaccini D.,Lenzi F.,Costa F.,Leonardi G.,Ricchiuti A.,Mumolo M. G.,Bellini M.,Blandizzi C.,Marchi S.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2011.04616.x/fullpdf

Reference43 articles.

1. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease;Winters;Gastroenterology,1987

2. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux;Csendes;Dis Esophagus,2003

3. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction;Pera;Gastroenterology,1993

4. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus;Cameron;Gastroenterology,1995

5. Barrett’s esophagus;Falk;Gastroenterology,2002

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett’s Esophagus;International Journal of Molecular Sciences;2023-07-11

2. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy;Helicobacter;2020-10-21

3. DIAGNOSIS, TREATMENT AND FOLLOW-UP OF BARRETT’S ESOPHAGUS: A SYSTEMATIC REVIEW;Arquivos de Gastroenterologia;2020-09

4. Barrett's esophagus: What do we need to know?;Disease-a-Month;2020-01

5. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial;The Lancet;2018-08